Literature DB >> 18385740

Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling.

Ilaria Malanchi1, Hector Peinado, Deepika Kassen, Thomas Hussenet, Daniel Metzger, Pierre Chambon, Marcel Huber, Daniel Hohl, Amparo Cano, Walter Birchmeier, Joerg Huelsken.   

Abstract

Continuous turnover of epithelia is ensured by the extensive self-renewal capacity of tissue-specific stem cells. Similarly, epithelial tumour maintenance relies on cancer stem cells (CSCs), which co-opt stem cell properties. For most tumours, the cellular origin of these CSCs and regulatory pathways essential for sustaining stemness have not been identified. In murine skin, follicular morphogenesis is driven by bulge stem cells that specifically express CD34. Here we identify a population of cells in early epidermal tumours characterized by phenotypic and functional similarities to normal bulge skin stem cells. This population contains CSCs, which are the only cells with tumour initiation properties. Transplants derived from these CSCs preserve the hierarchical organization of the primary tumour. We describe beta-catenin signalling as being essential in sustaining the CSC phenotype. Ablation of the beta-catenin gene results in the loss of CSCs and complete tumour regression. In addition, we provide evidence for the involvement of increased beta-catenin signalling in malignant human squamous cell carcinomas. Because Wnt/beta-catenin signalling is not essential for normal epidermal homeostasis, such a mechanistic difference may thus be targeted to eliminate CSCs and consequently eradicate squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385740     DOI: 10.1038/nature06835

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  263 in total

1.  Controversies in cancer stem cells: targeting embryonic signaling pathways.

Authors:  Naoko Takebe; S Percy Ivy
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

Review 2.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

3.  Tumour biology: Skin-cancer stem cells outwitted.

Authors:  Salvador Aznar Benitah
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

4.  Emerging strategies for the identification and targeting of cancer stem cells.

Authors:  Jun Dou; Ning Gu
Journal:  Tumour Biol       Date:  2010-03-25

5.  Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer.

Authors:  Cornelia Johanna Franziska Scheitz; Tae Seung Lee; David James McDermitt; Tudorita Tumbar
Journal:  EMBO J       Date:  2012-10-02       Impact factor: 11.598

Review 6.  A Wnt survival guide: from flies to human disease.

Authors:  Andy J Chien; William H Conrad; Randall T Moon
Journal:  J Invest Dermatol       Date:  2009-01-29       Impact factor: 8.551

Review 7.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

8.  Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.

Authors:  Tanya Stoyanova; Aaron R Cooper; Justin M Drake; Xian Liu; Andrew J Armstrong; Kenneth J Pienta; Hong Zhang; Donald B Kohn; Jiaoti Huang; Owen N Witte; Andrew S Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

Review 9.  Novel ablation methods for treatment of gliomas.

Authors:  Brittanie Partridge; John H Rossmeisl; Alexandra M Kaloss; Erwin Kristobal Gudenschwager Basso; Michelle H Theus
Journal:  J Neurosci Methods       Date:  2020-02-14       Impact factor: 2.390

Review 10.  Epithelial stem cells in adult skin.

Authors:  Ana Mafalda Baptista Tadeu; Valerie Horsley
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.